INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagnostic imaging services and related solutions in the U.S. Intuitive Surgical, Inc. manufactures the da Vinci Surgical System, a robotic surgical system used for minimally invasive surgical procedures.
BDF-GESTION sold 4,149 shares of Eli Lilly and Company; Transaction value was $3.1 million Transaction represents 0.37% of BDF-GESTION's 13F reportable assets under management Post-trade stake: 19,949 shares valued at $15.22 million as of September 30, 2025 Position now represents 1.8% of fund AUM, which places it outside the fund's top five holdings
Eli Lilly (LLY) shares have surged by 16% over the last month and are currently priced at $825. U.S. pharmaceutical stocks have done well of late, as large drugmakers such as Pfizer and AstraZeneca signed drug pricing agreements with the Trump Administration to cut prescription drug prices and boost domestic manufacturing investments.
Wall Street expects good news when Lilly announces its Q3 results on Oct. 30. Lilly's stock might not perform as you think it will, even if it beats analysts' estimates.
Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its burden on patients By Week 12, patients experienced a 55% reduction in daily episodes of bowel urgency from baseline, with severity reduced by more than half by Week 28 At Week 28, nearly one-third of p...
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound and Mounjaro. Since my article was published on September 8, Eli Lilly's stock price has risen by 13.1%. On October 24th, Eli Lilly surprised me by announcing its acquisition of Adverum Biotechnologies, a developer of gene therapies for the treatment of ocular diseases, for...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.